Literature DB >> 21281982

The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Govindarajan Thangavelu1, Kenneth M Murphy, Hideo Yagita, Louis Boon, Colin C Anderson.   

Abstract

The immune system of female H-2(b) (C57BL/6) mice is a strong responder against the male minor-H antigen. However rejection or acceptance of such weakly mismatched grafts depends on the type of tissue transplanted. The mechanism responsible for such spontaneous graft acceptance, and its relationship to the natural mechanisms of tolerance of self antigens is unknown. Co-inhibitory molecules negatively regulate immune responses, and are important for self tolerance. We examined whether co-inhibitory molecules play a critical role in "spontaneous" allograft tolerance. Naïve or donor sensitized diabetic female C57BL/6 (B6) wild type (WT), PD-1(-/-), and BTLA(-/-) mice were transplanted with freshly isolated syngeneic male islet grafts. The role of co-inhibitors during priming of anti-donor responses and graft challenge was also assessed using monoclonal antibodies targeting co-inhibitory receptors. Among the co-inhibitor (CTLA-4, PD-1) specific antibodies tested, only anti-PD-1 showed some potential to prevent spontaneous acceptance of male islet grafts. All BTLA(-/-) and almost all PD-1(-/-) recipients maintained the ability to spontaneously accept male islet grafts. While spontaneous graft acceptance in naïve recipients was only weakly PD-1 dependent, tolerance induced by the accepted islets was found to be highly PD-1 dependent. Furthermore, spontaneous graft acceptance in pre-sensitized recipients showed an absolute requirement for recipient PD-1 but not BTLA. Thus, the PD-1 pathway, involved in self tolerance, plays a critical role in spontaneous tolerance induced by weakly mismatched grafts in naïve recipients and spontaneous graft acceptance in pre-sensitized recipients.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281982      PMCID: PMC4030676          DOI: 10.1016/j.imbio.2011.01.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  50 in total

1.  HY peptides modulate transplantation responses to skin allografts.

Authors:  Edward James; Diane Scott; Jian-Guo Chai; Maggie Millrain; Phillip Chandler; Elizabeth Simpson
Journal:  Int Immunol       Date:  2002-11       Impact factor: 4.823

2.  Cutting edge: B and T lymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation.

Authors:  Christine Deppong; Twyla I Juehne; Michelle Hurchla; Lindzy D Friend; Dulari D Shah; Christine M Rose; Traci L Bricker; Laurie P Shornick; Erika C Crouch; Theresa L Murphy; Michael J Holtzman; Kenneth M Murphy; Jonathan M Green
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

3.  PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft.

Authors:  M Morita; M Fujino; G Jiang; Y Kitazawa; L Xie; M Azuma; H Yagita; S Nagao; A Sugioka; Y Kurosawa; S Takahara; J Fung; S Qian; L Lu; X-K Li
Journal:  Am J Transplant       Date:  2009-11-04       Impact factor: 8.086

4.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

Review 5.  Review lecture. Immunology of H-Y antigen and its role in sex determination.

Authors:  E Simpson
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-11-22

6.  PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.

Authors:  Weigang Wang; Katie Carper; Frances Malone; Yvette Latchman; James Perkins; Yaowen Fu; Jorge Reyes; Wei Li
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

7.  Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.

Authors:  Wenda Gao; Gülçin Demirci; Terry B Strom; Xian Chang Li
Journal:  Transplantation       Date:  2003-09-27       Impact factor: 4.939

8.  Pancreatic islets induce CD4(+) [corrected] CD25(-)Foxp3(+) [corrected] T-cell regulated tolerance to HY-mismatched skin grafts.

Authors:  Il-Hee Yoon; Seung-Eun Choi; Yong-Hee Kim; Seung-Ha Yang; Ji-Hyun Park; Chan-Sik Park; Youngji Kim; Jung-Sik Kim; Sang-Joon Kim; Elizabeth Simpson; Chung-Gyu Park
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

9.  PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue.

Authors:  Brent H Koehn; Mandy L Ford; Ivana R Ferrer; Keshawna Borom; Shivaprakash Gangappa; Allan D Kirk; Christian P Larsen
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  "Indirect" acute islet allograft destruction in nonobese diabetic mice is independent of donor major histocompatibility complex and requires host B lymphocytes.

Authors:  T Kupfer; J N Beilke; K Pham; J Buhrman; R G Gill
Journal:  Transplant Proc       Date:  2008-03       Impact factor: 1.066

View more
  7 in total

Review 1.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

2.  PD-1 regulates T cell proliferation in a tissue and subset-specific manner during normal mouse pregnancy.

Authors:  Michelle T Shepard; Elizabeth A Bonney
Journal:  Immunol Invest       Date:  2013-06-19       Impact factor: 3.657

3.  Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.

Authors:  Vineet Kwatra; Narayan V Karanth; Kelum Priyadarshana; Michail Charakidis
Journal:  J Med Case Rep       Date:  2017-03-19

4.  Egr2 and 3 control inflammation, but maintain homeostasis, of PD-1high memory phenotype CD4 T cells.

Authors:  Alistair Lj Symonds; Wei Zheng; Tizong Miao; Haiyu Wang; TieShang Wang; Ruth Kiome; Xiujuan Hou; Suling Li; Ping Wang
Journal:  Life Sci Alliance       Date:  2020-07-24

Review 5.  Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.

Authors:  Michael J Grant; Nicholas DeVito; April K S Salama
Journal:  Melanoma Manag       Date:  2018-10-26

6.  Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.

Authors:  Csaba Kerepesi; Tibor Bakacs; Ralph W Moss; Shimon Slavin; Colin C Anderson
Journal:  Cancer Immunol Immunother       Date:  2020-03-09       Impact factor: 6.968

7.  Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.

Authors:  R Kleef; R Nagy; A Baierl; V Bacher; H Bojar; D L McKee; R Moss; N H Thoennissen; M Szász; T Bakacs
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.